Literature DB >> 27302402

Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia/reperfusion injury but does not influence heart failure development.

Harmen G Booij1, Hongjuan Yu2, Rudolf A De Boer1, Cees W A van de Kolk3, Bart van de Sluis4, Jan M Van Deursen5, Wiek H Van Gilst1, Herman H W Silljé1, B Daan Westenbrink6.   

Abstract

AIMS: A kinase interacting protein 1 (AKIP1) stimulates physiological growth in cultured cardiomyocytes and attenuates ischaemia/reperfusion (I/R) injury in ex vivo perfused hearts. We aimed to determine whether AKIP1 modulates the cardiac response to acute and chronic cardiac stresses in vivo. METHODS AND
RESULTS: Transgenic mice with cardiac-specific overexpression of AKIP1 (AKIP1-TG) were created. AKIP1-TG mice and their wild-type (WT) littermates displayed similar cardiac structure and function. Likewise, cardiac remodelling in response to transverse aortic constriction or permanent coronary artery ligation was identical in AKIP1-TG and WT littermates, as evidenced by serial cardiac magnetic resonance imaging and pressure-volume loop analysis. Histological indices of remodelling, including cardiomyocyte cross-sectional diameter, capillary density, and left ventricular fibrosis were also similar in AKIP1-TG mice and WT littermates. When subjected to 45 min of ischaemia followed by 24 h of reperfusion, AKIP1-TG mice displayed a significant two-fold reduction in myocardial infarct size and reductions in cardiac apoptosis. In contrast to previous reports, AKIP1 did not co-immunoprecipitate with or regulate the activity of the signalling molecules NF-κB, protein kinase A, or AKT. AKIP1 was, however, enriched in cardiac mitochondria and co-immunoprecipitated with a key component of the mitochondrial permeability transition (MPT) pore, ATP synthase. Finally, mitochondria isolated from AKIP1-TG hearts displayed markedly reduced calcium-induced swelling, indicative of reduced MPT pore formation.
CONCLUSIONS: In contrast to in vitro studies, AKIP1 overexpression does not influence cardiac remodelling in response to chronic cardiac stress. AKIP1 does, however, reduce myocardial I/R injury through stabilization of the MPT pore. These findings suggest that AKIP1 deserves further investigation as a putative treatment target for cardioprotection from I/R injury during acute myocardial infarction. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  AKIP1; Heart failure; Hypertrophy; Mitochondrial permeability transition pore; Reperfusion injury

Mesh:

Substances:

Year:  2016        PMID: 27302402     DOI: 10.1093/cvr/cvw161

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  12 in total

1.  ATPase Inhibitory Factor-1 Disrupts Mitochondrial Ca2+ Handling and Promotes Pathological Cardiac Hypertrophy through CaMKIIδ.

Authors:  Mario G Pavez-Giani; Pablo I Sánchez-Aguilera; Nils Bomer; Shigeki Miyamoto; Harmen G Booij; Paula Giraldo; Silke U Oberdorf-Maass; Kirsten T Nijholt; Salva R Yurista; Hendrik Milting; Peter van der Meer; Rudolf A de Boer; Joan Heller Brown; Herman W H Sillje; B Daan Westenbrink
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

2.  Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure.

Authors:  Eline L Vegter; Ekaterina S Ovchinnikova; Herman H W Silljé; Laura M G Meems; Atze van der Pol; A Rogier van der Velde; Eugene Berezikov; Adriaan A Voors; Rudolf A de Boer; Peter van der Meer
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

3.  Does BCA3 Play a Role in the HIV-1 Replication Cycle?

Authors:  Michaela Rumlová; Ivana Křížová; Jaroslav Zelenka; Jan Weber; Tomáš Ruml
Journal:  Viruses       Date:  2018-04-20       Impact factor: 5.048

4.  A-kinase interacting protein 1 (AKIP1) associates with advanced overall disease condition, tumor properties, and unfavorable prognosis in hepatocellular carcinoma patients.

Authors:  Tao Fang; Qi Lu
Journal:  J Clin Lab Anal       Date:  2020-03-05       Impact factor: 2.352

5.  Plasma levels of heart failure biomarkers are primarily a reflection of extracardiac production.

Authors:  Weijie Du; Arnold Piek; E Marloes Schouten; Cees W A van de Kolk; Christian Mueller; Alexandre Mebazaa; Adriaan A Voors; Rudolf A de Boer; Herman H W Silljé
Journal:  Theranostics       Date:  2018-07-30       Impact factor: 11.556

Review 6.  Impacts of exercise intervention on various diseases in rats.

Authors:  Ruwen Wang; Haili Tian; Dandan Guo; Qianqian Tian; Ting Yao; Xingxing Kong
Journal:  J Sport Health Sci       Date:  2019-10-28       Impact factor: 7.179

7.  MiR-320 regulates cardiomyocyte apoptosis induced by ischemia-reperfusion injury by targeting AKIP1.

Authors:  Zhi-Qiang Tian; Hong Jiang; Zhi-Bing Lu
Journal:  Cell Mol Biol Lett       Date:  2018-08-28       Impact factor: 5.787

8.  Mitochondrial therapy for doxorubicin cardiomyopathy: nuclear factor-κB to the rescue?

Authors:  Kirsten Theresa Nijholt; Berend Daan Westenbrink; Rudolf Allert de Boer
Journal:  Cardiovasc Res       Date:  2020-05-01       Impact factor: 10.787

9.  Pharmacological myeloperoxidase (MPO) inhibition in an obese/hypertensive mouse model attenuates obesity and liver damage, but not cardiac remodeling.

Authors:  Arnold Piek; Debby P Y Koonen; Elisabeth-Maria Schouten; Eva L Lindtstedt; Erik Michaëlsson; Rudolf A de Boer; Herman H W Silljé
Journal:  Sci Rep       Date:  2019-12-10       Impact factor: 4.379

10.  Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction.

Authors:  Salva R Yurista; Herman H W Silljé; Harry van Goor; Jan-Luuk Hillebrands; Hiddo J L Heerspink; Luiz de Menezes Montenegro; Silke U Oberdorf-Maass; Rudolf A de Boer; B Daan Westenbrink
Journal:  Cardiovasc Drugs Ther       Date:  2020-06       Impact factor: 3.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.